DOCSLIB.ORG

Biomarkers for Ischaemic Stroke

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biomarkers for Ischaemic Stroke BIOMARKERS FOR ISCHAEMIC STROKE NAZEEHA HASAN A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY SUPERVISORS: DR PANKAJ SHARMA DR ROBERT EDWARDS DEPARTMENT OF MEDICINE IMPERIAL COLLEGE LONDON DECEMBER 2013 ABSTRACT Background: Current diagnostic, prognostic and risk stratification tools are inadequate for effective ischaemic stroke management. Hypothesising that –omics approaches can be used to detect novel candidate biomarkers for ischaemic stroke, this thesis aimed to evaluate the current status of biomarkers for ischaemic stroke and develop strategies for biomarker discovery. Methods: Systematic literature review and individual patient data meta-analyses were performed to assess current candidate biomarkers associated with ischaemic stroke. Proteomic SELDI-TOF MS profiling was undertaken to identify novel blood-based protein biomarkers for the diagnosis of acute ischaemic stroke, consisting of a pilot study and a subsequent well- powered discovery study of 104 patients. In an integrative genomics study, transcriptomics data from carotid endarterectomy samples was combined with a genome-wide association study meta-analysis and subjected to functional enrichment analysis to detect differential gene expression or alternative splicing profiles that may be under the control of a genetic variant. Results: Systematic review and meta-analysis concluded that no current candidate biomarkers could be recommended for routine clinical practice, supporting the pursuit of novel biomarkers for ischaemic stroke and informing the design of subsequent experimental studies. SELDI-TOF MS detected two plasma protein ions, m/z 3699 and m/z 6640, which could differentiate between acute cerebral ischaemia and stroke mimics. Protein ion m/z 6640, identified as ApoC-1, highlighted the role of lipid dysregulation and was postulated to be a novel candidate biomarker for acute cerebral ischaemia. Integrative genomics provided evidence for the genetic regulation of cytoskeletal organisation and extracellular matrix remodelling processes in carotid disease. The LTBP4 gene was found to be a candidate risk biomarker for ischaemic stroke by predicting plaque instability and rupture. Conclusions: This work provides workflows for successful biomarker discovery using innovative –omics approaches, highlights key pathogenic pathways and identifies novel candidate biomarkers for ischaemic stroke diagnosis and risk stratification. 3 The work presented in this thesis is original and my own. Information derived from other sources has been appropriately acknowledged and referenced. The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work. 4 PUBLICATIONS AND PRESENTATIONS PUBLICATIONS *Hasan N, Altman DG, on behalf of the SU:GAR Group. Association of Admission Glucose Levels with Symptomatic Intracerebral Haemorrhage Following Acute Stroke Thrombolysis: Quantification of Risk Using Individual Patient Data. [Manuscript in Preparation]. Cotlarciuc I, Malik R, Holliday EG, Ahmadi KR, Pare G, Psaty BM, Fornage M, Hasan N, Rinne PE, Ikram MA, Markus HS, Rosand J, Mitchell BD, Kittner SJ, Meschia JF, van Meurs JBJ, Uitterlinden AG, Worrall BB, Dichgans M, Sharma P, on behalf of METASTROKE and the International Stroke Genetics Consortium. Effect of genetic variants associated with plasma homocysteine levels on stroke risk. Stroke, 2014 [In Publication]. Yadav S, Cotlarciuc I, Munroe PB, Khan MS, Nalls MA, Bevan S, Cheng YC, Chen WM, Malik R, McCarthy NS, Holliday EG, Speed D, Hasan N, Pucek M, Rinne PE, Sever P, Stanton A, Shields DC, Maguire JM, McEvoy M, Scott RJ, Ferrucci L, Macleod MJ, Attia J, Markus HS, Sale MM, Worrall BB, Mitchell BD, Dichgans M, Sudlow C, Meschia JF, Rothwell PM, Caulfield M, Sharma P; International Stroke Genetics Consortium. Genome- Wide Analysis of Blood Pressure Variability and Ischemic Stroke. Stroke. 2013;44(10):2703-2709. *Hasan N. Cardiovascular disease as a measure of sustainable development. Journal of the Royal Society of Medicine Cardiovascular Disease. 2013;2: 2048004013491731. Yadav S, Hasan N, Marjot T, Khan MS, Prasad K, Bentley P, Sharma P. Detailed analysis of gene polymorphisms associated with ischemic stroke in South Asians. PLoS One. 2013; 8(3):e57305. *Hasan N, McColgan P, Bentley P, Edwards RJ, Sharma P. Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. Br J Clin Pharmacol. 2012;74(2):230-40. Brooke J, Hasan N & Sharma P. Efficacy of information interventions in reducing transfer anxiety from a critical care setting to a general ward: a systematic review and meta-analysis. Journal of Critical Care. 2012;27(4): 425.e9-15. Shalhoub J, Davies KJ, Hasan N, Thapar A, Sharma P, Davies AH. The utility of collaborative biobanks for cardiovascular research. Angiology. 2012;63(5):367-77. Marjot T, Yadav S, Hasan N, Bentley P & Sharma P. Genes associated with adult cerebral thrombosis. Stroke 2011; 42: 913-918. ORAL AND POSTER PRESENTATIONS *Platform Presentation: Integrative Genomics for Symptomatic Carotid Disease. International Stroke Genetics Consortium meeting, Lund, Sweden. November 2013. *Poster Presentation: Whole Genome Exon Array of Human Carotid Plaques. Imperial College London Department of Medicine Young Scientist Day, London, UK. April 2012. *Platform presentation: Towards the Identification of Blood Biomarkers for Acute Stroke. London Cardiovascular Society, London Medical Society, London, UK. April 2012. *Poster Presentation: Whole Genome Exon Array of Human Carotid Plaques: Differential Gene Expression, Alternative Splicing and the Role of IRF5 in advanced lesion development. British Heart Foundation Centre of Research Excellence Symposium, Cambridge, UK. June 2011. *Platform Presentation: Too Sweet to Treat? Rethinking Current Glucose Guidelines for Thrombolytic Therapy. 5th UK Stroke Forum, Glasgow UK. December 2010. * Publications and presentations relevant to this thesis. 5 ACKNOWLEDGEMENTS First and foremost I would like to thank my supervisors: Dr Pankaj Sharma for his support and guidance throughout my PhD, and Dr Robert Edwards, with whom every conversation has been a humbling lesson in how to be a ‘good’ scientist. Special thanks go to the many people who have contributed their time and expertise to the completion of this thesis. I am particularly indebted to Dr Waheedah Abdul-Salam for dedicating her time and help to the proteomics study, as well as providing constant support throughout my PhD. To Dr Paul Bentley, Dr Peter McColgan, Muhammad Saleem-Khan, Professor Doug Altman and the collaborators of the SU:GAR group for their statistical guidance and contribution to the biomarker systematic review and individual patient data meta-analysis. I would like to thank Dr Joseph Shalhoub, Professor Alun Davies, Dr Daniah Trabzuni and Dr Mina Ryten for their involvement with gene expression profiling, as well as Dr Ioana Cotlarciuc, Dr Sunaina Yadav, and Dr Doug Speed for their advice throughout the integrative genomics study. Thank you to the members of the Imperial College Cerebrovascular Research Unit (ICCRU) for making the past four years so enjoyable. To my family and friends for their patience and support, especially Kartik, for being my rock, Madiha and Siddik for providing a home away from home, and little Samaya, for being my stressball and a much-needed source of sanity. And finally, to my parents. None of this would have been possible without their unwavering love and encouragement. This thesis is dedicated to them, and all those who have taught me. 6 CONTENTS ABSTRACT .............................................................................................................................................. 3 PUBLICATIONS AND PRESENTATIONS ................................................................................................... 5 ACKNOWLEDGEMENTS........................................................................................................................... 6 LIST OF FIGURES .................................................................................................................................. 12 LIST OF TABLES ................................................................................................................................... 14 ABBREVIATIONS .................................................................................................................................. 16 CHAPTER ONE: INTRODUCTION .................................................................................................................................... 19 1.1 The Burden of Vascular Disease and Stroke ................................................................................ 20 1.2 Stroke Aetiology and Classification ................................................................................................ 21 1.2.1 Ischaemic Stroke Subtypes .................................................................................................................. 21 1.2.2 Transient Ischaemic Attack ................................................................................................................. 24
Load more

Recommended publications
  • Und Serumspiegel Von S-100B Und GFAP Nach Schädelhirntrauma: Aussagekraft in Der Akutdiagnostik Und Möglicher Prognostischer Wert
    Aus dem Institut für Neuroradiologie der Universität zu Lübeck Direktor: Prof. Dr. med. D. Petersen ______________________________________________________ Plasma- und Serumspiegel von S-100B und GFAP nach Schädelhirntrauma: Aussagekraft in der Akutdiagnostik und möglicher prognostischer Wert Inauguraldissertation zur Erlangung der Doktorwürde der Universität zu Lübeck - Aus der medizinischen Fakultät - vorgelegt von Elke Steinmeier aus Braunschweig Lübeck, 2006 Erster Berichterstatter Priv. Doz. Dr. med. Ulrich Missler Zweiter Berichterstatter/ Berichterstatterin Priv. Doz. Dr. med. Jan Gliemroth Tag der mündlichen Prüfung 03.05.2007 Zum Druck genehmigt Lübeck, den 03.05.07 gez. Prof. Dr. med. Werner Solbach Dekan der Medizinischen Fakultät 2 Inhalt Inhalt 3 1. Grundlagen 5 1.1 Einleitung und Fragestellung 5 1.2 Schädelhirntrauma 8 1.3 Zerebrale Strukturproteine 12 1.4 Das S-100 Protein 13 1.4.1 Vorkommen der S-100 Monomere 14 1.4.2 Funktion der S-100 Proteine 15 1.5 Das saure gliale Faserprotein (GFAP) 16 1.5.1 Vorkommen des GFAP im menschlichen Körper 16 1.5.2 Funktion des GFAP Proteins 16 2. Patienten, Material und Methoden 18 2.1 Auswahl von Patienten und Kontrollpersonen 18 2.2 Probengewinnung und Verarbeitung 18 2.3 Material 19 2.3.1 Antikörper 19 2.3.2 Chemikalien und verwendete Pufferlösungen 19 2.3.2.1 Herstellung der Enhancement-Lösung 19 2.3.2.2 Herstellung des Waschpuffers 20 2.3.2.3 Herstellung des TRIS/HCl/NaCl-Puffers 20 2.4 Immunfluoreszenzassay zur Bestimmung des S-100B Proteins 20 2.5 Immunfluoreszenzassay zur Bestimmung des GFAP Proteins 22 2.6 Neurologische Beurteilungsskalen 23 2.6.1 Glasgow Coma Skala 23 2.6.2 Glasgow Outcome Skala 25 2.6.3 CCT-Skala 25 2.7 Statistische Methoden 26 3.
    [Show full text]
  • Indication Phase Route Country Name Role Country Type
    Alzheimer's Disease (Preclinical & Research) Drug Development Phase Organisations Drug Introduction Synonyms Mechanism Of Action Indication Phase Route Country Name Role Country Type Ownership IRX 4204 IRX 4204 is an orally bioavailable, first in class, AGN 194204 Retinoid X receptor agonists Prostate cancer Phase II PO USA Allergan Originator USA Large Pharma, Pharmaceutical Public retinoid X receptor (RXR; rexinoid) agonist being AGN-194204 Alzheimer's disease Preclinical PO USA Io Therapeutics Owner World Biopharmaceutical Private developed by Io Therapeutics. The initial focus is AGN194204 Parkinson's disease Preclinical PO USA Mount Sinai School of Medicine Collaborator USA University N/A for the treatment of castration-resistant prostate ALRT 4204 The Michael J. Fox Foundation for Parkinsons Research Collaborator USA Institution N/A cancer, but may also be developed for non-small cell lung cancer. IRX 4204 demonstrated activity ALRT-4204 against a variety of human cancers in vitro and ALRT4204 in animal models, including prostate, breast, IRX-4204 1 pancreatic, and lung [CONT.] IRX4204 NRX 194204 NRX 4204 NRX-194204 NRX-4204 NRX194204 NRX4204 VTP 194204 VTP-194204 VTP194204 Stem cell therapies - RNL BIO RNL BIO (South Korea) is researching and Adipose stem cell therapies - RNL BIO Cell replacements Facial hemiatrophy Phase II Parenteral South Korea Asan Medical Center Collaborator South Korea Hospital N/A developing stem cell therapies derived from adult Adult-derived stem cell therapies - RNL BIO Osteoarthritis Phase II Intra articular South Korea RNL BIO Originator South Korea Biotechnology sources, such as cord blood, placenta, hair Astrostem Thromboangiitis obliterans Phase II Parenteral South Korea RNL BIO Owner South Korea Biotechnology follicle and adipose (fat) tissue.
    [Show full text]
  • Mesh Terms for 2002
    Mesh Terms for Fiscal Year 2002 1,2-DIMETHYLHYDRAZINE 1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE 1,4-ALPHA-GLUCAN BRANCHING ENZYME 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE 1-ACYLGLYCEROPHOSPHOCHOLINE O-ACYLTRANSFERASE 1-BUTANOL 1-CARBOXYGLUTAMIC ACID 1-DEOXYNOJIRIMYCIN 1-METHYL-3-ISOBUTYLXANTHINE 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE 1-METHYL-4-PHENYLPYRIDINIUM 1-NAPHTHYLAMINE 1-NAPHTHYLISOTHIOCYANATE 1-OCTANOL 1-PHOSPHATIDYLINOSITOL 3-KINASE 1-PHOSPHATIDYLINOSITOL 4-KINASE 1-PROPANOL 1-SARCOSINE-8-ISOLEUCINE ANGIOTENSIN II 11-HYDROXYCORTICOSTEROIDS 12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID 15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOI 15-OXOPROSTAGLANDIN 13-REDUCTASE 16,16-DIMETHYLPROSTAGLANDIN E2 17 ALPHA-HYDROXYPROGESTERONE ALDOLASE 17-HYDROXYCORTICOSTEROIDS 17-HYDROXYPROGESTERONE 17-HYDROXYSTEROID DEHYDROGENASES 17-KETOSTEROIDS 18-HYDROXYCORTICOSTERONE 18-HYDROXYDESOXYCORTICOSTERONE 19-IODOCHOLESTEROL 2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES 2',5'-OLIGOADENYLATE SYNTHETASE 2,2'-DIPYRIDYL 2,3-DIKETOGULONIC ACID 2,3-DIPHOSPHOGLYCERATE 2,4,5-TRICHLOROPHENOXYACETIC ACID 2,4-DICHLOROPHENOXYACETIC ACID 2,4-DINITROPHENOL 2,5-DIMETHOXY-4-METHYLAMPHETAMINE 2,6-DICHLOROINDOPHENOL 2-ACETOLACTATE MUTASE 2-ACETYLAMINOFLUORENE 2-AMINO-5-PHOSPHONOVALERATE 2-AMINOADIPIC ACID 2-AMINOPURINE 2-CHLOROADENOSINE 2-DEHYDRO-3-DEOXYPHOSPHOHEPTONATE ALDOLASE 2-HYDROXY-5-NITROBENZYL BROMIDE 2-HYDROXYPHENETHYLAMINE 2-ISOPROPYLMALATE SYNTHASE 2-METHYL-4-CHLOROPHENOXYACETIC ACID 2-NAPHTHYLAMINE 2-PROPANOL 20-HYDROXYSTEROID DEHYDROGENASES
    [Show full text]
  • Insights from the Sequence Similarity of Zika Virus Proteins with the Human Nerve Proteins
    Open access www.bioinformation.net Hypothesis Volume 14(5) Insights from the sequence similarity of Zika virus proteins with the Human nerve proteins Prasanna Marsakatla1, Sujai Suneetha1, Joshua Lee2, Paari Dominic Swaminathan3, Logeshwaran Vasudevan4, Rachael Supriya1, Lavanya Moses Suneetha1* Received April 10, 2018; Revised April 23, 2018; Accepted April 30, 2018; Published May 31, 2018 1CODEWEL Nireekshana ACET, Narayanaguda, Hyderabad -500029, Telangana, India; 2York University, Department of Science, 4700 Keele St, Toronto, ON M3J 1P3, Canada; 3LSU Health Sciences Center, Center for Cardiovascular Diseases and Sciences Shreveport, LA, USA; 4Presidency College, Department of Zoology, Chennai-05, India; Lavanya Moses Suneetha – E:mail - [email protected]; Phone: +91-40-23221033; +91-9885150381; *Corresponding Author doi:10.6026/97320630014194 Abstract: Massive peptide sharing between the Zika virus polyprotein and host tissue proteins could elicit significant host-pathogen interactions and cross-reactions leading to autoimmune diseases. This study found similarities in the Zika V proteins and human nerve tissue proteins. 63 human nerve proteins were screened for similarities with the Zika V of which Neuromodulin, Nestin, Galanin, Bombesin, Calcium-binding protein were found to have similarities to the Zika V poly protein C at different sequence regions. These sequence similarities could be significant in regulating pathogenic interactions/autoimmunity, as Polyprotein C is known to be a virulent factor. Keywords: Zika V, Nerve tissue proteins, Neuropathogenesis, Bioinformatics, BLAST, Neuromodulin, Nestin, Bombesin, Galanin, Calcium-binding protein. Background: Tyro3, and TIM-1) facilitating the entry of the Zika V into The Zika Virus (Zika V), is an emerging infectious disease agent different tissue cells [7]. Cell culture experiments of the Zika V causing human birth defects.
    [Show full text]
  • Intiharin Biyokimyasal Belirteçleri Olarak Beyin Omurilik Sivisinda S100b Proteini Ve Serotonin Düzeylerinin Değerlendirilmesi
    T.C. SELÇUK ÜNİVERSİTESİ SAĞLIK BİLİMLERİ ENSTİTÜSÜ İNTİHARIN BİYOKİMYASAL BELİRTEÇLERİ OLARAK BEYİN OMURİLİK SIVISINDA S100B PROTEİNİ VE SEROTONİN DÜZEYLERİNİN DEĞERLENDİRİLMESİ Kamil Hakan DOĞAN DOKTORA TEZİ BİYOKİMYA (TIP) ANABİLİM DALI DANIŞMAN Prof. Dr. Mustafa ÜNALDI KONYA - 2012 T.C. SELÇUK ÜNİVERSİTESİ SAĞLIK BİLİMLERİ ENSTİTÜSÜ İNTİHARIN BİYOKİMYASAL BELİRTEÇLERİ OLARAK BEYİN OMURİLİK SIVISINDA S100B PROTEİNİ VE SEROTONİN DÜZEYLERİNİN DEĞERLENDİRİLMESİ Kamil Hakan DOĞAN DOKTORA TEZİ BİYOKİMYA (TIP) ANABİLİM DALI DANIŞMAN Prof. Dr. Mustafa ÜNALDI Bu araştırma Selçuk Üniversitesi Bilimsel Araştırma Projeleri Koordinatörlüğü tarafından 11102026 proje numarası ile desteklenmiştir. KONYA - 2012 ÖNSÖZ Adli Tıp Uzmanı olarak Biyokimya Anabilim Dalı’nda doktora eğitimine, Biyokimya biliminin Adli Tıp alanında pek çok yerde kullanılması ve Adli Tıp’ın gelişmesinde çok önemli bir yeri olması nedeniyle başladım. Eğitimim boyunca da, Biyokimya’nın derinliklerine indikçe, aslında rutinde Adli Tıp alanında kullandığımız pek çok bilginin tamamen biyokimyasal süreçlere ve temellere dayandığı ve bu alanda ilerlemenin ancak iyi bir biyokimya bilgisine ve nosyonuna sahip olmakla gerçekleştirilebileceğini daha iyi kavradım. Bu zorlu süreçte doktora eğitimim boyunca bilgi ve deneyimleri ile bana yol gösteren başta tez danışmanım kıymetli hocam Prof.Dr. Mustafa Ünaldı’ya, İlgisini ve desteğini sürekli hissettiğim Biyokimya Anabilim Dalı Başkanı kıymetli hocam Prof.Dr. İdris Mehmetoğlu’na, Eğitimime katkı sağlayan Biyokimya Anabilim Dalı’nın tüm değerli öğretim üyelerine ve laboratuvar personeline, Doktora çalışmasına başlamamda motivasyonumu sağlayan ve tez çalışmam boyunca örneklerin toplanmasına bizzat katkı sağlayan kıymetli hocam Doç.Dr.Şerafettin Demirci’ye, Örneklerin analizi aşamasında samimi desteğini gördüğüm Arş.Gör.Dr. Erkan Taşyürek’e, Bu çalışmanın yapılabilmesi için gerekli maddi desteği 11102026 nolu projeyle sağlayan Selçuk Üniversitesi Bilimsel Araştırma Projeleri Koordinatörlüğü’ne, Her zaman desteğini gördüğüm eşim Yrd.Doç.Dr.
    [Show full text]
  • Early Stage & Preclinical MOA Counts Early Stage & Preclinical Company
    Early Stage & Preclinical MOA counts Early Stage & Preclinical Company Activity MOA # of profiles Company # of profiles Aβ inhibitors 58 Merck & Co 12 Undefined 33 AstraZeneca 11 Immunostimulants 19 Pfizer 10 BACE1 protein inhibitors 18 Bristol-Myers Squibb 6 Tau protein inhibitors 13 Roche 6 APP secretase inhibitors 12 Wyeth 6 AChe inhibitors 8 GlaxoSmithKline 5 Alpha-synuclein inhibitors 7 Takeda 5 APP secretase modulators 7 University of California at Irvine 5 5-HT6 antagonists 7 Abbott Laboratories 4 Tau protein modulators 6 AbbVie 4 Amyloid beta-protein precursor inhibitors 5 Astellas Pharma 4 Antioxidants 5 Bayer HealthCare Pharmaceuticals 4 Cell replacements 5 Biogen Idec 4 Immunomodulators 5 Daewoong Pharmaceutical 4 NMDA receptor antagonists 5 Eli Lilly 4 Positron-emission tomography enhancers 5 Northwestern University 4 Alpha7 nicotinic acetylcholine receptor agonists 4 Suven Life Sciences 4 Amyloid inhibitors 4 Alzheimers Drug Discovery Foundation 3 Chelating agents 4 Boehringer Ingelheim 3 Nerve growth factor stimulants 4 CHDI 3 Neuron stimulants 4 ChemDiv 3 Serotonin 4 receptor agonists 4 Elan Corporation 3 Amyloid beta-protein modulators 3 EnVivo Pharmaceuticals 3 Calcium channel antagonists 3 JANSSEN Alzheimer Immunotherapy 3 Cathepsin S inhibitors 3 Johnson & Johnson Pharmaceutical Research & Development 3 G protein-coupled receptor modulators 3 Lay Line Genomics 3 Muscarinic M1 receptor agonists 3 Ligand Pharmaceuticals 3 Nicotinic receptor agonists 3 McGill University 3 Advanced glycosylation end-product receptor antagonists
    [Show full text]
  • William Nichol Whiteley
    Blood markers for the diagnosis and prognosis of stroke William Nichol Whiteley PhD by Research University of Edinburgh 2010 Whiteley W.N . Blood Markers in Stroke University of Edinburgh 2010 Table of contents Table of contents ................................................................................................................... 2 Table of tables........................................................................................................................ 7 Table of figures.................................................................................................................... 11 Abstract................................................................................................................................. 14 Declaration........................................................................................................................... 17 Publications and awards relating to the work of this thesis......................................... 18 Abbreviations ...................................................................................................................... 21 Acknowledgments and my contribution to the work of the thesis ............................. 24 Chapter 1. Introduction ............................................................................................... 26 The importance of diagnosis and prognosis ............................................................... 26 Aims of the thesis...........................................................................................................
    [Show full text]